{"filings":[{"id":1664999,"accession_number":"0001493152-26-033369","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2026-07-15T20:22:40+00:00","items":["4.01","9.01"],"status":"ready","headline":"RetinalGenix auditor Liebman Hymowitz resigns; Vilki & Co. appointed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Liebman Hymowitz resigned as auditor effective July 13, 2026; no disagreements with the company.","Prior audit reports included a going concern explanatory paragraph for years ended Dec 31, 2025 and 2024.","Vilki & Co. engaged as new independent auditor for fiscal year 2026, effective July 15, 2026.","No consultations with Vilki & Co. occurred before engagement on accounting or audit matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109548,"accession_number":"0001493152-26-012957","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RetinalGenix CFO Michael Cory Zwerling resigns effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Michael Cory Zwerling resigned effective immediately on March 22, 2026.","No successor or interim CFO has been announced.","CEO Jerry Katzman signed the Form 8-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179078,"accession_number":"0001493152-25-007703","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"RetinalGenix amends warrant to bar exercise until 2030 or 3 yrs after uplisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment restricts exercise of 28,014,540-share pre-funded warrant held by Sanovas Ophthalmology, LLC.","New exercise limitation: earlier of Feb 1, 2030 or 3rd anniversary of uplisting to Nasdaq or NYSE American.","CEO Jerry Katzman signed for both company and holder (Sanovas Ophthalmology, LLC).","No other terms of the warrant were modified; $100 consideration paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230897,"accession_number":"0001493152-24-013775","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2024-04-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Delaware court voids 3M Series F preferred shares issued to Halo Management in 2018","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court of Chancery of Delaware issued order on April 2, 2024 voiding 3,000,000 Series F Preferred shares.","Shares were issued to Halo Management LLC in 2018; board rescinded them in November 2021 for lack of consideration.","Company recorded the rescission in its accounts in Q4 2021; court order confirms the action.","Case: Sanovas, Inc. v. Lawrence J. Gerrans and Halo Management (C.A. No. 2020-0993-PAF)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266765,"accession_number":"0001493152-23-043870","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"RetinalGenix appoints Dr. Dessislava Boneva as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Boneva appointed to board effective December 4, 2023.","She is a trauma surgeon with board certifications in surgery and surgical critical care.","No family relationships or material interests with company executives.","Serves as Surgery Clerkship Director/Clinical Assistant Professor at Nova Southeastern University.","Fellow of American College of Surgeons with 20+ years of experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266764,"accession_number":"0001493152-23-043522","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"RetinalGenix appoints Virender Ahluwalia as Interim CFO; $300/hr, $15k base contingent on capital","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Virender Ahluwalia appointed Interim CFO effective Nov 30, 2023; over 25 years of finance experience.","Consulting agreement: $300/hour, $15,000 base compensation ($10,000 subject to company's capital balance).","Ahluwalia owns Trendz Network, LLC, which entered the consulting agreement; 30-day termination notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358357,"accession_number":"0001493152-22-020481","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"RetinalGenix appoints Vinay Mehindru, MD, MBA to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Vinay Mehindru, age 55, appointed director effective July 25, 2022.","He has over 25 years of healthcare experience; currently CEO of Exemplary Health.","Previously President of AdventHealth's clinically integrated networks (2014-2019) and CMO.","No family relationships or material interests with company directors or officers.","Appointment fills board seat; no departure of existing directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358356,"accession_number":"0001493152-22-018761","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2022-07-07T23:59:59+00:00","items":["1.01","2.01","3.02","8.01","9.01"],"status":"ready","headline":"RetinalGenix acquires DNA/GPS for 2M shares; combines retinal imaging with genetic mapping","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired all outstanding shares of DNA/GPS Inc. in exchange for 2,000,000 shares of RTGN common stock.","DNA/GPS is a pharmacogenetics company based in Tampa, FL, founded by Dr. Lawrence Perich.","Combined platform aims to enable home-based screening and diagnosis of systemic diseases like heart disease, Alzheimer's, Parkinson's.","Dr. Perich to join advisory board; platform expected to reduce reliance on costly procedures like CT, MRI, PET.","Shares issued in private placement exempt from registration under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395482,"accession_number":"0001493152-22-004875","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"RetinalGenix and Diopsys terminate 2019 Option Exchange Agreement; no options ever issued","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Termination effective Feb 14, 2022; Agreement from Oct 8, 2019 never had conditions satisfied.","No options were issued under the agreement, and the contemplated Exclusive Distribution Agreement was never negotiated.","Both parties are mutually released from any claims related to the Agreement and its termination.","RetinalGenix and Diopsys continue discussions toward a potential Exclusive Distribution Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414217,"accession_number":"0001493152-21-032831","cik":1836295,"company_name":"RetinalGenix Technologies Inc.","ticker":"RTGN","form_type":"8-K","filed_at":"2021-12-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"RetinalGenix exchanges 28M shares for pre-funded warrant; outstanding shares drop to 14.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 28,014,540 shares held by Sanovas Ophth for a pre-funded warrant to purchase same number of shares at $0.0001 per share.","Outstanding shares reduced from ~42.2M to 14,166,114 after cancellation of exchanged shares.","Transaction with related party: CEO Jerry Katzman is sole manager of Sanovas Ophth.","Warrant is immediately exercisable and terminates when exercised in full; no new cash received.","Issued under Section 3(a)(9) exemption; no additional consideration was paid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":75020000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}